SOCIETE DES PHARMACIENS DU CENTRE : revenue, balance sheet and financial ratios

SOCIETE DES PHARMACIENS DU CENTRE is a French company founded 49 years ago, specialized in the sector Traitement de données, hébergement et activités connexes. Based in ORLEANS (45100), this company of category PME shows in 2025 a revenue of 4.7 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SOCIETE DES PHARMACIENS DU CENTRE (SIREN 311337240)
Indicator 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016
Revenue 4 668 621 € 4 474 669 € 3 946 629 € 3 971 871 € 3 462 231 € 3 214 171 € 3 093 593 € 2 993 796 € 2 411 429 € 2 229 654 €
Net income 1 515 686 € 1 037 504 € 1 124 825 € 1 912 667 € 1 774 175 € 1 382 107 € 1 121 357 € 1 036 158 € 995 576 € 785 321 €
EBITDA 1 133 547 € 746 357 € 260 470 € 1 178 988 € 877 266 € 597 399 € 414 710 € 23 660 € -160 293 € -278 584 €
Net margin 32.5% 23.2% 28.5% 48.2% 51.2% 43.0% 36.2% 34.6% 41.3% 35.2%

Revenue and income statement

In 2025, SOCIETE DES PHARMACIENS DU CENTRE achieves revenue of 4.7 M€. Over the period 2016-2025, the company shows strong growth with a CAGR (compound annual growth rate) of +8.6%. Vs 2024: +4%. After deducting consumption (0 €), gross margin stands at 4.7 M€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 1.1 M€, representing 24.3% of revenue. Positive scissor effect: EBITDA margin improves by +7.6 pts, sign of improved operational efficiency. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 1.5 M€, i.e. 32.5% of revenue. This profit can be retained or distributed to shareholders.

Revenue (2025) ?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production

4 668 621 €

Gross margin (2025) ?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed

4 668 621 €

EBITDA (2025) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

1 133 547 €

EBIT (2025) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

2 012 407 €

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

1 515 686 €

EBITDA margin (2025) ?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability
5-10% : Average
< 5% : Low

24.3%

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 166%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 37%. The balance between equity and debt is satisfactory. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 15.7 years of cash flow to repay all financial debt. Beyond 7 years, banks generally consider credit risk as high. Cash flow represents 41.4% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

165.954%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

36.908%

Cash flow / Revenue (2025) ?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates

41.434%

Repayment capacity (2025) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

15.746

Asset age ratio (2025) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

21.6%

Solvency indicators evolution
SOCIETE DES PHARMACIENS DU CENTRE

Sector positioning

Debt ratio
165.95 2025
2023
2024
2025
Q1: 0.0
Med: 0.78
Q3: 40.2
Watch

In 2025, the debt ratio of SOCIETE DES PHARMACIENS D... (165.95) ranks in the top 25% of the sector. This ratio measures the weight of debt relative to equity. A high ratio may indicate excessive dependence on external financing.

Financial autonomy
36.91% 2025
2023
2024
2025
Q1: 13.06%
Med: 41.13%
Q3: 64.34%
Average

In 2025, the financial autonomy of SOCIETE DES PHARMACIENS D... (36.9%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Repayment capacity
15.75 years 2025
2023
2024
2025
Q1: 0.0 years
Med: 0.0 years
Q3: 1.43 years
Watch

In 2025, the repayment capacity of SOCIETE DES PHARMACIENS D... (15.75) ranks in the top 25% of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A long duration may signal heavy debt relative to repayment capacity.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 5412.08. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 1.1x. Coverage is limited: any activity downturn would jeopardize interest payments.

Liquidity ratio (2025) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

5412.08

Interest coverage (2025) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

1.149

Liquidity indicators evolution
SOCIETE DES PHARMACIENS DU CENTRE

Sector positioning

Liquidity ratio
5412.08 2025
2023
2024
2025
Q1: 141.74
Med: 232.37
Q3: 405.14
Excellent

In 2025, the liquidity ratio of SOCIETE DES PHARMACIENS D... (5412.08) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.

Interest coverage
1.15x 2025
2023
2024
2025
Q1: 0.0x
Med: 0.0x
Q3: 2.69x
Good -14 pts over 3 years

In 2025, the interest coverage of SOCIETE DES PHARMACIENS D... (1.1x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 27 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 83 days. Excellent situation: suppliers finance 56 days of the operating cycle (retail model). Overall, WCR represents 1224 days of revenue, i.e. 15.9 M€ to permanently finance. Over 2016-2025, WCR increased by +2459%, requiring additional financing.

Operating WCR (2025) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

15 878 120 €

Customer credit (2025) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

27 j

Supplier credit (2025) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

83 j

Inventory turnover (2025) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR in days of revenue (2025) ?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management

1224 j

WCR and payment terms evolution
SOCIETE DES PHARMACIENS DU CENTRE

Positioning of SOCIETE DES PHARMACIENS DU CENTRE in its sector

Comparison with sector Traitement de données, hébergement et activités connexes

Valuation estimate

Indicative estimate only : the number of comparable transactions in this sector is limited (33 transactions). This range of 480 223€ to 2 039 925€ is provided for information purposes only and requires in-depth analysis to be confirmed.

Estimated enterprise value 2025
Indicative
480k€ 870k€ 2039k€
870 956 € Range: 480 223€ - 2 039 925€
NAF 5 all-time
How is this estimate calculated?

This estimate is based on the analysis of 33 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Traitement de données, hébergement et activités connexes)

Compare SOCIETE DES PHARMACIENS DU CENTRE with other companies in the same sector:

Voir toutes les statistiques du secteur Traitement de données, hébergement et activités connexes

Frequently asked questions about SOCIETE DES PHARMACIENS DU CENTRE

What is the revenue of SOCIETE DES PHARMACIENS DU CENTRE ?

The revenue of SOCIETE DES PHARMACIENS DU CENTRE in 2025 is 4.7 M€.

Is SOCIETE DES PHARMACIENS DU CENTRE profitable?

Yes, SOCIETE DES PHARMACIENS DU CENTRE generated a net profit of 1.5 M€ in 2025.

Where is the headquarters of SOCIETE DES PHARMACIENS DU CENTRE ?

The headquarters of SOCIETE DES PHARMACIENS DU CENTRE is located in ORLEANS (45100), in the department Loiret.

Where to find the tax return of SOCIETE DES PHARMACIENS DU CENTRE ?

The tax return of SOCIETE DES PHARMACIENS DU CENTRE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SOCIETE DES PHARMACIENS DU CENTRE operate?

SOCIETE DES PHARMACIENS DU CENTRE operates in the sector Traitement de données, hébergement et activités connexes (NAF code 63.11Z). See the 'Sector positioning' section above to compare the company with its competitors.